Non-GLP-1 RA based glucose lowering drugs clinical trials

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

This study looks at the possible link between a type 2 diabetes medicine called exenatide and pancreatic cancer. Researchers are comparing patients who started exenatide with those who started other diabetes medicines, using health records from several European countries.